The FDA has approved a new indication for Arzerra to use in combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia.
The FDA has granted Orphan Drug designation to volasertib (Boehringer Ingelheim) for acute myeloid leukemia (AML).
AbbVie announced the initiation of a Phase 3 trial evaluating the safety and efficacy of veliparib in patients with previously untreated locally advanced or metastatic squamous non-small cell lung cancer.
Palonosetron and netupitant combo showed superior efficacy in controlling nausea and vomiting compared with palonosetron alone.
In a phase 1 study, the potent ALK inhibitor shows promise for treating NSCLC.
R.M. is a 58-year-old male recently diagnosed with stage IV pancreatic adenocarcinoma (Slide 1). He is a mechanical engineer ...
J.W. is a 55-year-old woman recently admitted to the hospital for worsening shortness of breath (Slide 1).
Relevant Medical History
Editorial Board Member Don Dizon, MD, answers some questions about issues in breast cancer treatment today.
ChemotherapyAdvisor.com Editorial Board Member Don S. Dizon discusses survivorship issues from the 2013 Breast Cancer Symposium.
Barbara Ann Burtness, MD
Steven Cohen, MD
E. David Crawford, MD
Don S. Dizon, MD, FACP
Jeffrey M. Farma, MD
Edith A. Perez, MD
Neal D. Shore, MD, FACS
Mark A. Socinski, MD
Martin Tallman, MD
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|